The Scheme's investment objective is to seek to provide a combination of capital growth and income.
Name | % Net Assets |
---|---|
HSBC Holdings | 8.0% |
Royal Dutch Shell | 7.3% |
GlaxoSmithKline | 7.3% |
Vodafone | 6.0% |
BP | 5.7% |
AstraZeneca | 5.5% |
Royal & Sun Alliance Insurance | 3.7% |
Unilever | 3.2% |
Logica | 2.7% |
RIO TINTO PLC | 2.7% |
Key | % Net Assets |
---|---|
HSBC Holdings | 8.0% |
Royal Dutch Shell | 7.3% |
GlaxoSmithKline | 7.3% |
Vodafone | 6.0% |
Other | 71.4% |
Date | 21-Nov-2024 |
---|---|
NAV | 276.50p |
Currency | GBP |
Change | -0.30p |
% | -0.11% |
YTD change | 21.30p |
YTD % | 8.35% |
Fund Inception | 30/06/2004 |
---|---|
Fund Manager | n/a |
TER | - |
Minimum Investment | |
---|---|
Initial | £500000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | n/a |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.01 |
Sharpe ratio | 0.20 |
You are here: research